NY-ESO-1 Protein Formulated in ISCOMATRIX Adjuvant Is a Potent Anticancer Vaccine Inducing Both Humoral and CD8+ T-Cell-Mediated Immunity and Protection against NY-ESO-1+ Tumors
暂无分享,去创建一个
T. Luft | F. Lemonnier | A. Suhrbier | S. Green | A. Sjölander | M. Pearse | J. Cebon | T. Le | E. Maraskovsky | Weisan Chen | Qiyuan Chen | T. Tai | L. Mateo | S. Sjölander | M. Schnurr | Kelly‐Anne Masterman | D. Drane
[1] I. Davis,et al. Tumor antigen processing and presentation depend critically on dendritic cell type and the mode of antigen delivery. , 2005, Blood.
[2] T. Luft,et al. ISCOM based vaccines for cancer immunotherapy. , 2004, Vaccine.
[3] A. Mowat,et al. Dendritic cell maturation enhances CD8+ T‐cell responses to exogenous antigen via a proteasome‐independent mechanism of major histocompatibility complex class I loading , 2003, Immunology.
[4] A. Mowat,et al. A role for dendritic cells in the priming of antigen-specific CD4+ and CD8+ T lymphocytes by immune-stimulating complexes in vivo. , 2003, International immunology.
[5] D. Purdie,et al. Durable complete clinical responses in a phase I/II trial using an autologous melanoma cell/dendritic cell vaccine , 2003, Cancer Immunology, Immunotherapy.
[6] Danila Valmori,et al. Multiepitope CD8(+) T cell response to a NY-ESO-1 peptide vaccine results in imprecise tumor targeting. , 2002, The Journal of clinical investigation.
[7] Yao-Tseng Chen,et al. Cancer/testis antigens: an expanding family of targets for cancer immunotherapy , 2002, Immunological reviews.
[8] Yao-Tseng Chen,et al. CD8+ T cell responses against a dominant cryptic HLA-A2 epitope after NY-ESO-1 peptide immunization of cancer patients , 2002, Proceedings of the National Academy of Sciences of the United States of America.
[9] T. Luft,et al. Functionally distinct dendritic cell (DC) populations induced by physiologic stimuli: prostaglandin E(2) regulates the migratory capacity of specific DC subsets. , 2002, Blood.
[10] I. Mellman,et al. Differential presentation of a soluble exogenous tumor antigen, NY-ESO-1, by distinct human dendritic cell populations , 2002, Proceedings of the National Academy of Sciences of the United States of America.
[11] A. Sjölander,et al. Local immune responses to influenza antigen are synergistically enhanced by the adjuvant ISCOMATRIX. , 2001, Vaccine.
[12] A. Suhrbier,et al. Cytotoxic T cell polyepitope vaccines delivered by ISCOMs. , 2001, Vaccine.
[13] Gerold Schuler,et al. Dendritic Cells as Vectors for Therapy , 2001, Cell.
[14] N. Altorki,et al. Immunohistochemical analysis of NY‐ESO‐1 antigen expression in normal and malignant human tissues , 2001, International journal of cancer.
[15] S. Chen,et al. Targeting dendritic cells to enhance DNA vaccine potency. , 2001, Cancer research.
[16] A. Suhrbier,et al. Immune responses to ISCOM formulations in animal and primate models. , 2001, Vaccine.
[17] S. Rosenberg,et al. CD4+ T cell recognition of MHC class II-restricted epitopes from NY-ESO-1 presented by a prevalent HLA DP4 allele: Association with NY-ESO-1 antibody production , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[18] D. Speiser,et al. CD8+ T-cell response to NY-ESO-1: relative antigenicity and in vitro immunogenicity of natural and analogue sequences. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.
[19] Steven A. Rosenberg,et al. Induction of Tumor-Reactive Cytotoxic T-Lymphocytes Using a Peptide from NY-ESO-1 Modified at the Carboxy-terminus to Enhance HLA-A2.1 Binding Affinity and Stability in Solution , 2001, Journal of immunotherapy.
[20] D. Speiser,et al. Efficient Simultaneous Presentation of NY-ESO-1/LAGE-1 Primary and Nonprimary Open Reading Frame-Derived CTL Epitopes in Melanoma , 2000, The Journal of Immunology.
[21] A. Osterhaus,et al. A randomized, double blind study in young healthy adults comparing cell mediated and humoral immune responses induced by influenza ISCOM vaccines and conventional vaccines. , 2000, Vaccine.
[22] D. Jäger,et al. Vaccination for Malignant Melanoma: Recent Developments , 2000, Oncology.
[23] J. Schlom,et al. Phase I clinical trial of a recombinant canarypoxvirus (ALVAC) vaccine expressing human carcinoembryonic antigen and the B7.1 co-stimulatory molecule , 2000, Cancer Immunology, Immunotherapy.
[24] D. Jäger,et al. Induction of primary NY-ESO-1 immunity: CD8+ T lymphocyte and antibody responses in peptide-vaccinated patients with NY-ESO-1+ cancers. , 2000, Proceedings of the National Academy of Sciences of the United States of America.
[25] A. Sjölander,et al. Induction of lymphocyte recruitment in the absence of a detectable immune response. , 2000, Vaccine.
[26] B. Fox,et al. Divergent Roles for CD4+ T Cells in the Priming and Effector/Memory Phases of Adoptive Immunotherapy1 , 2000, The Journal of Immunology.
[27] V Brusic,et al. NY-ESO-1 encodes DRB1*0401-restricted epitopes recognized by melanoma-reactive CD4+ T cells. , 2000, Cancer research.
[28] D. Speiser,et al. Naturally occurring human lymphocyte antigen-A2 restricted CD8+ T-cell response to the cancer testis antigen NY-ESO-1 in melanoma patients. , 2000, Cancer research.
[29] F. Gudat,et al. NY-ESO-1 tumour associated antigen is a cytoplasmic protein detectable by specific monoclonal antibodies in cell lines and clinical specimens , 2000, British Journal of Cancer.
[30] O. Tsitsilonis,et al. Tumor-Specific CD4+ T Lymphocytes from Cancer Patients Are Required for Optimal Induction of Cytotoxic T Cells Against the Autologous Tumor , 2000, Journal of Immunology.
[31] Yao-Tseng Chen,et al. CT10: A new cancer‐testis (CT) antigen homologous to CT7 and the MAGE family, identified by representational‐difference analysis , 2000, International journal of cancer.
[32] D. Jäger,et al. Identification of Ny-Eso-1 Epitopes Presented by Human Histocompatibility Antigen (Hla)-Drb4*0101–0103 and Recognized by Cd4+T Lymphocytes of Patients with Ny-Eso-1–Expressing Melanoma , 2000, The Journal of experimental medicine.
[33] A. Enk,et al. Vaccination with Mage-3a1 Peptide–Pulsed Mature, Monocyte-Derived Dendritic Cells Expands Specific Cytotoxic T Cells and Induces Regression of Some Metastases in Advanced Stage IV Melanoma , 1999, The Journal of experimental medicine.
[34] F. Lemonnier,et al. An HLA-A2 polyepitope vaccine for melanoma immunotherapy. , 1999, Journal of Immunology.
[35] D. Jäger,et al. Humoral immune responses of cancer patients against "Cancer-Testis" antigen NY-ESO-1: correlation with clinical events. , 1999, International journal of cancer.
[36] F. Ennis,et al. Augmentation of human influenza A virus-specific cytotoxic T lymphocyte memory by influenza vaccine and adjuvanted carriers (ISCOMS). , 1999, Virology.
[37] P. Ricciardi-Castagnoli,et al. Fcγ Receptor–mediated Induction of Dendritic Cell Maturation and Major Histocompatibility Complex Class I–restricted Antigen Presentation after Immune Complex Internalization , 1999, The Journal of experimental medicine.
[38] J. Bates,et al. Studies on experimental adjuvanted influenza vaccines: comparison of immune stimulating complexes (Iscoms) and oil-in-water vaccines. , 1998, Vaccine.
[39] D. Jäger,et al. Simultaneous Humoral and Cellular Immune Response against Cancer–Testis Antigen NY-ESO-1: Definition of Human Histocompatibility Leukocyte Antigen (HLA)-A2–binding Peptide Epitopes , 1998, The Journal of experimental medicine.
[40] M. Rolph,et al. Recombinant viruses as vaccines and immunological tools. , 1997, Current opinion in immunology.
[41] F. Lemonnier,et al. HLA-A2.1–restricted Education and Cytolytic Activity of CD8+ T Lymphocytes from β2 Microglobulin (β2m) HLA-A2.1 Monochain Transgenic H-2Db β2m Double Knockout Mice , 1997, The Journal of experimental medicine.
[42] Yao-Tseng Chen,et al. A testicular antigen aberrantly expressed in human cancers detected by autologous antibody screening. , 1997, Proceedings of the National Academy of Sciences of the United States of America.
[43] P. Matzinger,et al. Is cancer dangerous to the immune system? , 1996, Seminars in immunology.
[44] D. Moss,et al. Induction of protective cytotoxic T cells to murine cytomegalovirus by using a nonapeptide and a human-compatible adjuvant (Montanide ISA 720) , 1995, Journal of virology.